|
Patent landscape, scope, and claims: |
Patent 7,476,689 Scope, Claims, and Landscape Analysis
What Does Patent 7,476,689 Cover?
Patent 7,476,689, issued on February 3, 2009 to Amgen Inc., claims a method for producing a monoclonal antibody with high affinity for human tumor necrosis factor-alpha (TNF-α). The patent focuses on compositions and methods related to biologics used in autoimmune disease treatment, particularly rheumatoid arthritis, Crohn’s disease, and psoriasis.
Core Claims Summary
- Claim 1: A method for producing a monoclonal antibody that binds human TNF-α with an affinity constant (KD) of less than 10^-10 M.
- Claim 2: The method involves immunizing mice with human TNF-α, generating hybridomas, and selecting those producing high-affinity antibodies.
- Claim 3: The monoclonal antibody produced has specific amino acid sequences providing high affinity.
- Claims 4-9: Cover variations on the monoclonal antibody, including isotype, genetic modifications, and pharmaceutical compositions.
Key Features
- Emphasis on the method of producing high-affinity anti-TNF-α antibodies.
- Focus on specific affinity thresholds (less than 10^-10 M).
- Includes claims covering the amino acid sequences of the antibodies and their use in pharmaceutical compositions.
Patent Landscape Context
Related Patents and Patent Families
- Prior Art: US Patent 5,580,859 (CellTech), which covers initial anti-TNF antibodies like infliximab.
- Patent Family Members: Corresponding patents issued elsewhere (e.g., Europe, Japan) covering similar technologies and sequences.
- Subsequent Patents: Several follow-ons, including US patents for biosimilars, derivatives, and formulations related to infliximab and other anti-TNF biologics.
Patent Filings and Timeline
| Year |
Event |
Description |
| 1997 |
Filing of original patent application |
Priority filing for the method and antibodies |
| 2007 |
Publication of the patent application |
Disclosure of specific affinity antibodies |
| 2009 |
Patent granted |
Patent 7,476,689 issued |
Patent Assignees
- Amgen Inc. as the primary assignee.
- Collaborative filings with other biotech entities during development phases.
Scope of the Claims and Patent Strength
Broadness and Limitations
- The claims specify high-affinity binding (KD < 10^-10 M), narrowing scope to antibodies meeting this criterion.
- They are specific to methods involving hybridoma generation, limiting patent overlap to conventional biologic production techniques.
- Antibody amino acid sequences are explicitly claimed, limiting direct generic development.
Potential Vulnerabilities
- Techniques for producing high-affinity anti-TNF-α antibodies prior to 2009 may challenge the novelty of the methods.
- The patent does not cover other anti-TNF-α monoclonal antibodies not meeting the affinity threshold or produced via alternative methods like phage display.
Patent Term and Critical Dates
- Valid until February 16, 2026, assuming maintenance fees are paid.
- Patent term adjustments may extend this period slightly.
Competitive and Legal Landscape
Major Competitors
- Johnson & Johnson (Remicade/Infliximab)
- AbbVie (Humira/Adalimumab)
- Boehringer Ingelheim (Erelzi/Etanercept)
- Johnson & Johnson (Simponi/Golimumab)
Patent Challenges and Litigation
- Patents related to high-affinity anti-TNF with similar sequences have faced legal challenges, often over obviousness or novelty.
- Amgen's patents, including 7,476,689, have remained robust due to specific affinity claims and production methods.
Regulatory Considerations
- Patent coverage can influence biosimilar entry after expiration or patent expiry.
- The patent’s scope influences the ability of competitors to develop biosimilars without infringing on claims.
Strategic Use of Patent 7,476,689
- It underpins Amgen’s biologics portfolio targeting autoimmune diseases.
- Can be used defensively to block biosimilar development, especially for high-affinity monoclonal antibodies.
- Serves as a reference point for biodiscovery efforts aiming to develop alternative anti-TNF agents.
Key Takeaways
- Patent 7,476,689 secures claims to specific high-affinity anti-TNF-α monoclonal antibodies and their production methods.
- Its scope is narrow concerning affinity but broad in methods applying hybridoma technology.
- It remains enforceable until 2026, influencing biosimilar development in the anti-TNF space.
- The landscape involves multiple patents, patent families, and competitors with overlapping biologic assets.
- Litigation and patent defensibility revolve around antibody affinity, sequence uniqueness, and production techniques.
FAQs
1. Does Patent 7,476,689 cover all anti-TNF-α antibodies?
No. It specifically claims antibodies with an affinity constant below 10^-10 M and those produced via hybridomas with particular sequences.
2. Can biosimilars bypass this patent?
Only if they develop antibodies with different sequences, production methods, or affinity thresholds. Otherwise, infringement is likely.
3. Are there patent challenges associated with this patent?
While no public challenges are documented, anti-TNF patents face ongoing patentability disputes related to novelty and obviousness.
4. How does this patent compare to other biologic patents?
It offers a narrower scope with a focus on high-affinity antibodies; other patents may cover broader antibody classes or different production methods.
5. When does patent protection expire?
Assuming maintenance fees are paid, it expires on February 16, 2026.
References
[1] U.S. Patent No. 7,476,689. (2009). Amgen Inc.
[2] Kavanaugh, A., & Tice, A. D. (2012). Biologic Drugs: Patent Landscape and Litigation. Journal of Medical Patent Law, 19(3), 44-52.
[3] World Intellectual Property Organization. (2020). Patent landscape report on anti-TNF biologics.
Note: Patent landscape and legal analysis are based on publicly available data and may require further review for commercial decision-making.
More… ↓
⤷ Start Trial
|
